TY - JOUR
T1 - Soluble CD40 ligand release in patients with stable coronary artery disease during elective stent implantation
T2 - Effect of drug-eluting stent over bare metal stent
AU - Dündar, Cihan
AU - Kizilirmak, Filiz
AU - Tigen, Kürşat
AU - Izgi, Akin
AU - Karaahmet, Tansu
AU - Pala, Selçuk
AU - Oduncu, Vecih
AU - Erkol, Ayhan
AU - Bulut, Mustafa
AU - Kirma, Cevat
PY - 2013
Y1 - 2013
N2 - Objectives: We aimed to determine the effect of drug-eluting stent (DES) implantation on soluble CD40 ligand (sCD40L) levels in patients with stable coronary artery disease undergoing stent replacement. Study design: Eighty-nine consecutive patients (33 women, 56 men; mean age 61±10 years) with stable coronary artery disease undergoing stent replacement were recruited. Pre- and post-procedural blood samples were collected for sCD40L analysis, and differences in plasma levels were calculated and expressed as delta sCD40L. Total size and length of implanted stents and pre- and post-dilatation procedures were recorded for each patient, for possible impact on sCD40L release. Patients were followed for one year following procedures for possible adverse cardiac events such as death, myocardial infarction and revascularization. Results: Forty-nine patients received bare metal stent (BMS) and 40 patients received DES. There were no differences between BMS- and DES-implanted patients in terms of age, stent size and length, and delta sCD40L plasma levels. Delta sCD40L was correlated only with total implanted stent length (r=0.374, p<0.001). Delta sCD40L levels were divided into quartiles for better determination of the procedural parameters that are effective on biomarker release. Total stent length (p=0.008), stent size (p=0.038) and pre-dilatation procedure (p=0.034) were the statistically differing parameters between delta sCD40L quartiles. Although statistically non-significant, all three adverse events were observed in patients with the highest quartile (p=0.179). Conclusion: Procedural sCD40L release did not differ between DES- and BMS-implanted stable coronary artery disease patients. Total implanted stent length, stent size and pre-dilatation procedure were the influential parameters on procedural sCD40L release.
AB - Objectives: We aimed to determine the effect of drug-eluting stent (DES) implantation on soluble CD40 ligand (sCD40L) levels in patients with stable coronary artery disease undergoing stent replacement. Study design: Eighty-nine consecutive patients (33 women, 56 men; mean age 61±10 years) with stable coronary artery disease undergoing stent replacement were recruited. Pre- and post-procedural blood samples were collected for sCD40L analysis, and differences in plasma levels were calculated and expressed as delta sCD40L. Total size and length of implanted stents and pre- and post-dilatation procedures were recorded for each patient, for possible impact on sCD40L release. Patients were followed for one year following procedures for possible adverse cardiac events such as death, myocardial infarction and revascularization. Results: Forty-nine patients received bare metal stent (BMS) and 40 patients received DES. There were no differences between BMS- and DES-implanted patients in terms of age, stent size and length, and delta sCD40L plasma levels. Delta sCD40L was correlated only with total implanted stent length (r=0.374, p<0.001). Delta sCD40L levels were divided into quartiles for better determination of the procedural parameters that are effective on biomarker release. Total stent length (p=0.008), stent size (p=0.038) and pre-dilatation procedure (p=0.034) were the statistically differing parameters between delta sCD40L quartiles. Although statistically non-significant, all three adverse events were observed in patients with the highest quartile (p=0.179). Conclusion: Procedural sCD40L release did not differ between DES- and BMS-implanted stable coronary artery disease patients. Total implanted stent length, stent size and pre-dilatation procedure were the influential parameters on procedural sCD40L release.
KW - Angioplasty, transluminal, percutaneous coronary
KW - Biological markers/blood
KW - Cd40 ligand/blood
KW - Coronary artery disease/ blood
KW - Drug-eluting stents
KW - Platelet aggregation inhibitors
KW - Stents
UR - http://www.scopus.com/inward/record.url?scp=84900528452&partnerID=8YFLogxK
U2 - 10.5543/tkda.2013.64600
DO - 10.5543/tkda.2013.64600
M3 - Article
C2 - 24351940
AN - SCOPUS:84900528452
SN - 1016-5169
VL - 41
SP - 675
EP - 682
JO - Turk Kardiyoloji Dernegi Arsivi
JF - Turk Kardiyoloji Dernegi Arsivi
IS - 8
ER -